Recent advances in the development of antimuscarinic agents for overactive bladder

Trends in Pharmacological Sciences

Volumn 31, Issue 10, 2010, Pages 470-475

  Smith, Ariana L ^a   Wein, Alan J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BELLADONNA ALKALOID; DARIFENACIN; DICYCLOVERINE; FESOTERODINE; FLAVOXATE; GELNIQUE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OPIATE; OXYBUTYNIN; PLACEBO; PROPANTHELINE BROMIDE; PROPIVERINE; SANCTURA XR; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; ELDERLY CARE; HUMAN; NOCTURIA; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MUSCARINIC ANTAGONISTS; PREVALENCE; URINARY BLADDER, OVERACTIVE;

EID: 77956933845     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.07.004     Document Type: Review

References (50)

1. Cartwright R., et al. Current management of overactive bladder. Curr. Opin. Obstet. Gynecol. 2008, 20:489-495.
2. Abrams P., et al. The standardisation of terminology of lower urinary tract function: report from the Standarisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002, 21:167-178.
3. Chapple C.R., et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur. Urol. 2008, 54:543-562.
4. Andersson K.E. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology 2004, 63:32-41.
5. Kelleher C.J., et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Brit. J. Obstet. Gynaecol. 1997, 104:988-993.
6. Chapple C.R. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000, 55:47-49. (discussion 50).
7. Pesce, F. et al. (2003) Long-term anticholinergic therapy: duration and causes of discontinuation. In International Continence Society, Paris France, Aug 25-27.
8. Andersson K.E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004, 3:46-53.
9. Andersson K.E., Yoshida M. Antimuscarinics and the overactive detrusor-which is the main mechanism of action?. Eur. Urol. 2003, 43:1-5.
10. Abrams P., et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J. Urol. 2006, 175:999-1004.
11. Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol. Urodyn. 2010, 29:112-115.
12. De Laet K., et al. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol. Urodyn. 2006, 25:156-161.
13. Iijima K., et al. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur. Urol. 2007, 52:842-847.
14. Yoshida M., et al. Non-neuronal cholinergic system in human bladder urothelium. Urology 2006, 67:425-430.
15. Birder L.A., et al. Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. Am. J. Physiol. Renal. Physiol. 2003, 285:F423-F429.
16. Fry C.H., et al. The function of suburothelial myofibroblasts in the bladder. Neurourol. Urodyn. 2007, 26:914-919.
17. Finney S.M., et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?. BJU Int. 2006, 98:503-507.
18. Volpicelli L., Levey A.I. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog. Brain Res. 2004, 145:59-66.
19. Eglen R.M., et al. Muscarinic acetylcholine receptor subtypes in smooth muscle. Trends Pharmacol. Sci. 1994, 15:114-119.
20. Hedge S.S., Eglen R.M. Muscarinic receptor subtypes modulating smoth muscle contractility in the urinary bladder. Life Sci. 1999, 64:419-428.
21. Chess-Williams R., et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharmacol. 2001, 21:243-248.
22. Alabaster V.A. Discovery and development of selective M3 antagonists for clinical use. Life Sci. 1997, 60:1053-1060.
23. Bschleipfer T., et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 2007, 80:2303-2307.
24. Andersson K.E., et al. Urothelial effects of oral antimuscarinic agents. Curr. Urol. Rep. 2008, 9:459-464.
25. Mukerji G., et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J. Urol. 2006, 176:367-373.
26. Matsumoto Y., et al. Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats. Urology 2010, 75:862-867.
27. Andersson K.E., et al. Prevalence of cardiovascular comorbidities in patients treated with antimuscarinics for overactive bladder (OAB) [abstract]. Neurourol. Urodyn. 2007, 26:653-654.
28. Andersson K.E. The concept of uroselectivity. Eur. Urol. 1998, 33:7-11.
29. Sand P.K. The evolution of transdermal therapy for overactive bladder. Curr. Urol. Rep. 2009, 10:338-341.
30. Staskin D.R., et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J. Urol. 2009, 181:1764-1772.
31. Staskin D.R., Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin. Pharmacother. 2009, 10:3103-3111.
32. Caramelli, K.E. et al. (2008) Steady-state bioavailability of oxybutynin topical gel at 3 different application sites. In American Society of Consultant Pharmacists, New Orleans, LA, Nov 19-22.
33. Chapple C., et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur. Urol. 2007, 52:1204-1212.
34. Malhotra B., et al. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr. Med. Chem. 2009, 16:4481-4489.
35. Michel M.C. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin. Pharmacother. 2008, 9:1787-1796.
36. Khullar V., et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008, 71:839-843.
37. Herschorn S., et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010, 105:58-66.
38. Pak R.W., et al. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr. Urol. Rep. 2003, 4:436-440.
39. Zinner N.R. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin. Pharmacother. 2005, 6:1409-1420.
40. Silver N., et al. Pharmacokinetics of once-daily trospium chloride 60mg extended release and twice-daily trospium chloride 20mg in healthy adults. J. Clin. Pharmacol. 2010, 50:143-150.
41. Staskin D.R., et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J. Urol. 2007, 178:978-983.
42. Dmochowski R.R., et al. Trospium 60mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008, 71:449-454.
43. MacDiarmid S., et al. The effects of reformulation: improved therapeutic index. Curr. Urol. Rep. 2008, 9:465-471.
44. Todorova A., et al. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. 2001, 41:636-644.
45. Andersson K.E., Wein A.J. Pharmacologic management of storage and emptying failure. Campbell-Walsh Urology 2007, Saunders, Philadelphia. 9th edn.
46. Andersson K.E., et al. Pharmacological treatment of urinary incontinence. Incontinence 2009, Health Publication Limited, London, (Edition 21). 4th edn.
47. Kay G.G., et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J. Am. Geriatr. Soc. 2005, 53:2195-2201.
48. Pakulski C., et al. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med. Sci. Monit. 2000, 6:314-318.
49. Staskin D.R., et al. Initial assessment of urinary and faecal incontinence in adult male and female patients. Incontinence 2009, Health Publication Limited, London, (Edition 21). 4th edn.
50. Payne C., et al. Research. In Incontinence 2009, Health Publication Limited, London, (Edition 21). 4th edn.